4/A: Nuvectis Pharma Director Amends Filing to Correct Stock Purchase Prices and Include Additional Transactions

Charles Mosseri Marlio, a director of Nuvectis Pharma, Inc., amended a previous SEC filing to correct the prices of common stock acquired and include transactions from May 9, 2025.

Summary

• Charles Mosseri Marlio, a director at Nuvectis Pharma, Inc., filed an amendment to a Form 4.
• The amendment corrects the price of securities acquired in previously reported transactions.
• It also includes transactions that occurred on May 9, 2025, which were not initially reported.
• The reported transactions involve the purchase of common stock through Emerald Hill Ventures SARL SPF, of which Charles Mosseri Marlio is the beneficial owner.
• On May 8, 2025, purchases were made at prices of $8.99, $8.71 and $8.97 per share.
• On May 9, 2025, purchases were made at prices of $8.947, $8.9041 and $8.976 per share.
• Following these transactions, the total amount of common stock beneficially owned indirectly by Mosseri Marlio through Emerald Hill Ventures SARL SPF is 2,936,594 shares.

Sentiment

Score: 5

Explanation: This is a routine regulatory filing, so the sentiment is neutral.

Industry Context

Form 4 filings are a routine part of insider trading regulations, providing transparency into the transactions of company insiders.

Key Dates

Keywords

Nuvectis Pharma, SEC Form 4, Beneficial Ownership, Stock Transactions, Charles Mosseri Marlio, Emerald Hill Ventures, Amendment